An Australian Biotechnology company Aravax has developed a product using selected fragments of peanut proteins that switches off allergic reactions. The product is designed to be safer, more rapid and more convenient than other approaches currently under development.
According to a news source,the company has just commenced clinical trials of the potentially life-changing product and anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.
In the first ever trial of its product known as PVX108, Aravax will evaluate the safety and tolerability of single and repeated administration across a wide range of doses to determine an appropriate dosing regimen. This double-blinded and placebo-controlled trial commenced dosing on 10 May, with the first group of subjects safely receiving the lowest dose of PVX108. The trial is being conducted at CMAX Clinical Research in Adelaide and at Nucleus Network in Melbourne.
Aravax’s technology is underpinned by over a decade of research led by Professor Robyn O’Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust and the National Health and Medical Research Council. In 2015, Aravax secured over $4.85 million from the Medical Research Commercialisation Fund (MRCF) to develop the technology through to initial clinical trials.